Save on Triumeq with Coupons, Discounts & Savings Programs

Triumeq is the brand name for abacavir/dolutegravir/lamivudine is available as an oral tablet.

Triumeq is available as an oral tablet containing 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine.

Triumeq is a single-tablet regimen used to treat human immunodeficiency virus (HIV) infections.

Triumeq is a combination of 3 medications:

• Dolutegravir is an integrase inhibitor. Integrase is an enzyme (protein) that the HIV virus uses to enter your cells and make more copies of itself. Dolutegravir works by blocking integrase, therefore preventing HIV viruses from spreading.
• Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTIs). They block an enzyme called reverse transcriptase, which prevents the HIV virus from making copies of itself and spreading.

The recommended dose of Triumeq is one tablet daily with or without food.

Triumeq is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. You should not use this medication in the following:

• Presence of HLA-B*5701 allele
• Prior hypersensitivity reaction to abacavir, dolutegravir, or lamivudine
• Coadministration with dofetilide
• Moderate or severe liver impairment

Common side effects of Triumeq:

• Insomnia
• Headache
• Fatigue

Serious side effects are rare with Triumeq. Contact your healthcare provider immediately if you experience any of the following:

• Severe allergic reactions: fever, rash, nausea, vomiting, diarrhea, belly pain, extreme tiredness, body aches, trouble breathing, sore throat, cough
• Serious liver problems: nausea, vomiting, not feeling hungry, pain in the right side of the stomach, yellowing of the whites of the eyes or skin, dark-colored urine, light-colored stool
• Too much lactic acid in the blood: Weakness, tiredness, dizziness, stomach pain, nausea, vomiting, fast heartbeat, muscle pain, arms and legs feeling cold

The following medications may interact with Triumeq:

• Drugs that induce th UGT1A3, UGT1A9, BCRP, and P-gp enzymes

GlaxoSmithKline

Triumeq can raise the risk for neural tube defects in babies if taken during early pregnancy. If you can become pregnant, your provider will ask you to take a pregnancy test before starting this medication. They’ll also discuss with you about birth control options during your treatment with Triumeq. Your provider might only suggest Triumeq to be taken in the second or third trimester of pregnancy if the benefit is greater than the risk of harm to the unborn baby.

• Abacavir/Dolutegravir/Lamivudine